Don’t just sense presence. Sense a threat.

Only the Aptima® HPV assay and Aptima® HPV 16 18/45 Genotype assay detect both HPV presence and activity to target the infections most likely to lead to cervical disease — helping physicians maximize the benefits of screening while minimizing potential harm.

Run the Aptima HPV and HPV genotype assays simultaneously – from a single patient sample – on the Panther® system, and deliver results for both assays at once

- The Aptima HPV genotype assay targets HPV types 16, 18 and 45, which show higher carcinogenic potential relative to all other high-risk HPV types.¹

- The addition of HPV type 45 to the Aptima HPV genotype assay identifies more women at risk for adenocarcinoma, with minimal impact to colposcopy rate.²

To support better patient care, the Aptima HPV assay demonstrates improved specificity while offering the same excellent sensitivity as compared to DNA-based tests³

The Aptima HPV assay showed 24% fewer false positives than DNA-based tests in the NILM arm of the CLEAR trial.³

- Minimizes potential for overtreatment
- Minimizes difficult patient conversations

With longer intervals between cervical cancer screenings, identifying patients at risk requires excellent sensitivity.

Clinical sensitivity for ≥ CIN3⁴-19,*

*Represents clinical data from multiple published sources. The clinical studies represented within these sources were conducted using different study designs.

*Clinical sensitivity for ≥ CIN2.
The right targets to identify the right treatment

The Aptima HPV assay identifies high-risk HPV infections by targeting E6/E7 mRNA. Studies show that targeting E6/E7 mRNA identifies both the presence and activity of a high-risk HPV infection. The right targets to identify the right treatment to maximize the benefits of cervical cancer screening while minimizing potential harm. The characteristics align with current clinical practice guidelines, which are designed to maximize the benefits of cervical cancer screening while minimizing potential harm.

<table>
<thead>
<tr>
<th>mRNA and Cervical Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal cervical epithelium</td>
</tr>
<tr>
<td>HPV DNA levels decrease</td>
</tr>
</tbody>
</table>

The Aptima HPV assay offers a combination of the same excellent sensitivity and improved specificity as compared with DNA-based tests. These performance characteristics align with current clinical practice guidelines, which are designed to maximize the benefits of cervical cancer screening while minimizing potential harm.

References:

SS-00267-001 Rev. 001 © 2015 Hologic, Inc. All rights reserved. Hologic, Science of Sure, Aptima, Panther and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.